Results 41 to 50 of about 4,265 (97)

Diameter of Parathyroid Glands Measured by Computed Tomography as a Predictive Indicator for Response to Cinacalcet in Dialysis Patients with Secondary Hyperparathyroidism

Kidney & Blood Pressure Research, 2015
Background/Aims: Cinacalcet is one of the important treatments of secondary hyperparathyroidism (SHPT). We evaluated the role of computed tomography (CT) for parathyroid glands (PTGs) to determine the response to cinacalcet therapy in dialysis patients ...
Yu Ah Hong, Yoo Sun Cho, Sun Woo Kim, Mi Yeon Jung, Eun Ah Lee, Gang Jee Ko, Heui Jung Pyo, Soon Young Hwang, Sangil Suh, Young Joo Kwon   +9 more
doaj   +1 more source

Refractory tertiary hyperparathyroidism after calcimimetics and delayed parathyroidectomy in a kidney transplant recipient

Kidney Research and Clinical Practice, 2012
Persistent hyperparathyroidism affects renal outcomes and mortality. After kidney transplantation, cinacalcet is not approved as treatment for hyperparathyroidism. Parathyroidectomy, on the other hand, reverses electrolytes and mineral bone metabolism in
Ekamol Tantisattamo, David D. Ono
doaj   +1 more source

Changes of Serum Total and Free Testosterone Concentrations in Male Chronic Hemodialysis Patients with Secondary Hyperparathyroidism in Response to Cinacalcet Treatment

Kidney & Blood Pressure Research, 2016
Background/Aims: Calcium sensing receptor (CaSR) is expressed, among others also in testis. Cinacalcet binds to the CaSR, increases sensitivity of CaSR to serum calcium and is used in the treatment of secondary hyperparathyroidism (sHPT) in chronic ...
Piotr Kuczera, Marcin Adamczak, Andrzej Wiecek   +2 more
doaj   +1 more source

Cinacalcet Treatment Significantly Improves All-Cause and Cardiovascular Survival in Dialysis Patients: Results from a Meta-Analysis

Kidney & Blood Pressure Research, 2019
Objective: To assess the long-term effects including all-cause mortality, cardiovascular mortality, and fracture incidence, of cinacalcet on secondary hyperparathyroidism (SHPT) in patients on dialysis.
Yuan Zu, Xiangxue Lu, Jinghong Song, Ling Yu, Han Li, Shixiang Wang   +5 more
doaj   +1 more source

Long-Term Efficacy and Safety of Evocalcet in Japanese Patients with Secondary Hyperparathyroidism Receiving Hemodialysis

Scientific Reports, 2019
Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease (CKD), and as the disease progresses SHPT is associated with systemic consequences, termed CKD-mineral and bone disorder.
Keitaro Yokoyama, Ryutaro Shimazaki, Masafumi Fukagawa, Tadao Akizawa, On behalf of Evocalcet Study Group   +4 more
doaj   +1 more source

A Meta-analysis of Cinacalcet in the treatment of dialysis patients with secondary hyperparathyroidism

Linchuang shenzangbing zazhi, 2018
Objective To evaluate the efficacy and safety of cinacalcet in the treatment of dialysis patients with seondary hyperparathyroidism. Methods Retrieved from Pumed,Embase,Cochrane Library,OVID, CNKI, SinoMed, Wanfang data-base.
LV Yuan, XU Cheng-yun
doaj  

Efficacy of low-dose cinacalcet on alternate days for the treatment of secondary hyperparathyroidism in hemodialysis patients: a single-center study

International Journal of Nephrology and Renovascular Disease, 2017
Pongsathorn Gojaseni, Dolnapa Pattarathitinan, Anutra Chittinandana Division of Nephrology, Department of Medicine, Bhumibol Adulyadej Hospital, Directorate of Medical Services, Royal Thai Air Force, Bangkok, Thailand Introduction: Cinacalcet ...
Gojaseni P, Pattarathitinan D, Chittinandana A   +2 more
doaj  

Cinacalcet Efficacy in Hyperparathyroidism-Chronic Kidney Disease-Non-Dialysis, Hemodialysis, Peritoneal Dialysis, Kidney Transplantation: Critical Review. [PDF]

Biomedicines
Lewandowski D, Miedziaszczyk M, Lacka K, Idasiak-Piechocka I.   +3 more
europepmc   +1 more source

Safety evaluation of cinacalcet: Signal mining and analysis of adverse events based on the FAERS database. [PDF]

PLoS One
Cao J, Yang N, Huang C.
europepmc   +1 more source

Real-world evaluation of cinacalcet on hard outcomes in hemodialysis patients in Saudi Arabia. [PDF]

BMC Nephrol
Abdelrahman RM, Abdallah AMA, Ahmed AA, Musa TH, Arbab IA, Abuelgasim EO, Jalal M, Ahmed KO, Hassan YA, Altrefe Z, Ahmed HB.   +10 more
europepmc   +1 more source